Concepts (346)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Psychomotor Performance | 73 | 2012 | 505 | 6.520 |
Why?
|
| Analgesics, Opioid | 32 | 2014 | 513 | 4.370 |
Why?
|
| Oxycodone | 14 | 2013 | 35 | 4.260 |
Why?
|
| Nitrous Oxide | 28 | 2010 | 107 | 3.780 |
Why?
|
| Affect | 42 | 2011 | 397 | 3.040 |
Why?
|
| Morphine | 19 | 2014 | 130 | 2.370 |
Why?
|
| Narcotics | 12 | 2012 | 72 | 2.170 |
Why?
|
| Anesthetics, Inhalation | 13 | 2018 | 102 | 1.980 |
Why?
|
| Double-Blind Method | 64 | 2018 | 1791 | 1.950 |
Why?
|
| Cross-Over Studies | 45 | 2018 | 397 | 1.910 |
Why?
|
| Substance-Related Disorders | 18 | 2011 | 451 | 1.660 |
Why?
|
| Cognition | 23 | 2011 | 635 | 1.330 |
Why?
|
| Dose-Response Relationship, Drug | 42 | 2019 | 1973 | 1.310 |
Why?
|
| Ethanol | 11 | 2011 | 270 | 1.110 |
Why?
|
| Choice Behavior | 12 | 2008 | 165 | 1.090 |
Why?
|
| Pain | 10 | 2013 | 426 | 1.070 |
Why?
|
| Motivation | 8 | 2013 | 310 | 1.050 |
Why?
|
| Alcohol Drinking | 8 | 2009 | 287 | 1.050 |
Why?
|
| Methyl Ethers | 6 | 2008 | 34 | 1.000 |
Why?
|
| Adult | 104 | 2019 | 28721 | 0.990 |
Why?
|
| Arousal | 13 | 2005 | 173 | 0.940 |
Why?
|
| Smoking | 11 | 2013 | 653 | 0.880 |
Why?
|
| Opioid-Related Disorders | 9 | 2012 | 232 | 0.870 |
Why?
|
| Analgesics | 4 | 2013 | 132 | 0.850 |
Why?
|
| Male | 107 | 2019 | 45863 | 0.800 |
Why?
|
| Hydrocodone | 3 | 2008 | 8 | 0.770 |
Why?
|
| Female | 98 | 2019 | 50028 | 0.730 |
Why?
|
| Carisoprodol | 2 | 2011 | 4 | 0.710 |
Why?
|
| Analgesics, Non-Narcotic | 5 | 2008 | 50 | 0.700 |
Why?
|
| Psychomotor Disorders | 4 | 2008 | 20 | 0.670 |
Why?
|
| Sex Characteristics | 4 | 2010 | 339 | 0.660 |
Why?
|
| Pain Measurement | 10 | 2013 | 378 | 0.640 |
Why?
|
| Drug Interactions | 13 | 2012 | 245 | 0.620 |
Why?
|
| Humans | 126 | 2019 | 96105 | 0.610 |
Why?
|
| Cold Temperature | 8 | 2004 | 162 | 0.590 |
Why?
|
| Fentanyl | 9 | 1996 | 87 | 0.590 |
Why?
|
| Butorphanol | 4 | 2004 | 9 | 0.590 |
Why?
|
| Euphoria | 6 | 2010 | 47 | 0.570 |
Why?
|
| Memory | 7 | 2012 | 229 | 0.520 |
Why?
|
| Behavior | 5 | 1999 | 87 | 0.520 |
Why?
|
| Emotions | 4 | 2011 | 377 | 0.480 |
Why?
|
| Sex Factors | 5 | 2019 | 1133 | 0.460 |
Why?
|
| Muscle Relaxants, Central | 2 | 2011 | 11 | 0.440 |
Why?
|
| Propofol | 6 | 1996 | 95 | 0.430 |
Why?
|
| Nausea | 2 | 2013 | 182 | 0.420 |
Why?
|
| Hemodynamics | 10 | 2008 | 775 | 0.410 |
Why?
|
| Isoflurane | 4 | 2018 | 69 | 0.410 |
Why?
|
| Immersion | 4 | 2004 | 22 | 0.410 |
Why?
|
| Hydromorphone | 3 | 2011 | 11 | 0.410 |
Why?
|
| Healthy Volunteers | 1 | 2014 | 157 | 0.410 |
Why?
|
| Prescription Drug Misuse | 1 | 2013 | 13 | 0.400 |
Why?
|
| Marijuana Smoking | 5 | 1992 | 28 | 0.400 |
Why?
|
| Analysis of Variance | 10 | 2009 | 908 | 0.390 |
Why?
|
| Naltrexone | 1 | 2014 | 139 | 0.390 |
Why?
|
| Injections, Intravenous | 14 | 2001 | 238 | 0.380 |
Why?
|
| Anticonvulsants | 2 | 2011 | 133 | 0.380 |
Why?
|
| GABA Modulators | 1 | 2012 | 8 | 0.370 |
Why?
|
| Alprazolam | 1 | 2012 | 4 | 0.370 |
Why?
|
| Young Adult | 10 | 2014 | 7025 | 0.360 |
Why?
|
| Pupil | 5 | 2014 | 20 | 0.360 |
Why?
|
| Neurotoxicity Syndromes | 1 | 2011 | 29 | 0.350 |
Why?
|
| gamma-Aminobutyric Acid | 1 | 2011 | 87 | 0.350 |
Why?
|
| Administration, Inhalation | 10 | 2008 | 203 | 0.340 |
Why?
|
| Surveys and Questionnaires | 14 | 2011 | 2860 | 0.330 |
Why?
|
| Food Deprivation | 4 | 1992 | 23 | 0.330 |
Why?
|
| Analgesia | 3 | 1999 | 64 | 0.320 |
Why?
|
| Receptors, Opioid, mu | 4 | 2014 | 49 | 0.320 |
Why?
|
| Midazolam | 6 | 1996 | 49 | 0.320 |
Why?
|
| Pain Threshold | 4 | 1998 | 63 | 0.320 |
Why?
|
| Blood Pressure | 7 | 2005 | 926 | 0.310 |
Why?
|
| Acetaminophen | 2 | 2008 | 61 | 0.300 |
Why?
|
| Mental Recall | 5 | 2007 | 173 | 0.300 |
Why?
|
| Reaction Time | 7 | 2012 | 323 | 0.300 |
Why?
|
| Dextroamphetamine | 4 | 1992 | 108 | 0.290 |
Why?
|
| Codeine | 3 | 2005 | 12 | 0.290 |
Why?
|
| Anxiety | 1 | 2011 | 339 | 0.280 |
Why?
|
| Reference Values | 8 | 2009 | 674 | 0.280 |
Why?
|
| Alcoholic Intoxication | 1 | 2008 | 37 | 0.280 |
Why?
|
| Drug Combinations | 4 | 2011 | 214 | 0.270 |
Why?
|
| Caffeine | 3 | 2018 | 86 | 0.270 |
Why?
|
| Naloxone | 2 | 1999 | 72 | 0.260 |
Why?
|
| Anesthetics, Intravenous | 2 | 1997 | 43 | 0.260 |
Why?
|
| Central Nervous System Depressants | 2 | 1997 | 45 | 0.250 |
Why?
|
| Meperidine | 2 | 1999 | 11 | 0.250 |
Why?
|
| Narcotic Antagonists | 3 | 2014 | 170 | 0.250 |
Why?
|
| Fasting | 3 | 1992 | 164 | 0.250 |
Why?
|
| Automobile Driver Examination | 1 | 2006 | 1 | 0.250 |
Why?
|
| Drug Prescriptions | 2 | 2008 | 151 | 0.240 |
Why?
|
| Impulsive Behavior | 1 | 2009 | 290 | 0.240 |
Why?
|
| Task Performance and Analysis | 1 | 2006 | 92 | 0.240 |
Why?
|
| Automobile Driving | 1 | 2006 | 33 | 0.240 |
Why?
|
| Motor Skills | 1 | 2006 | 80 | 0.230 |
Why?
|
| Histamine H2 Antagonists | 1 | 2005 | 13 | 0.230 |
Why?
|
| Tramadol | 1 | 2005 | 14 | 0.230 |
Why?
|
| Carbon Monoxide | 8 | 1992 | 98 | 0.230 |
Why?
|
| Proton Pump Inhibitors | 1 | 2005 | 34 | 0.220 |
Why?
|
| Administration, Oral | 6 | 2011 | 688 | 0.220 |
Why?
|
| Cognition Disorders | 2 | 2005 | 244 | 0.220 |
Why?
|
| Substance Abuse Detection | 3 | 2013 | 12 | 0.220 |
Why?
|
| Valerian | 1 | 2004 | 3 | 0.220 |
Why?
|
| Plant Preparations | 1 | 2004 | 20 | 0.210 |
Why?
|
| Dextropropoxyphene | 1 | 2004 | 2 | 0.210 |
Why?
|
| Lorazepam | 4 | 2005 | 14 | 0.210 |
Why?
|
| Anesthetics | 3 | 1999 | 56 | 0.210 |
Why?
|
| Alcoholism | 2 | 1999 | 191 | 0.210 |
Why?
|
| Gastroesophageal Reflux | 1 | 2005 | 121 | 0.200 |
Why?
|
| Drug and Narcotic Control | 1 | 2003 | 7 | 0.200 |
Why?
|
| Respiration | 7 | 1999 | 281 | 0.200 |
Why?
|
| Anesthesia Recovery Period | 3 | 2018 | 55 | 0.200 |
Why?
|
| Marijuana Abuse | 2 | 1994 | 30 | 0.200 |
Why?
|
| Heart Rate | 6 | 2014 | 518 | 0.200 |
Why?
|
| Tropanes | 1 | 2002 | 2 | 0.190 |
Why?
|
| Nicotine | 5 | 1993 | 210 | 0.190 |
Why?
|
| Preanesthetic Medication | 1 | 2002 | 5 | 0.180 |
Why?
|
| Dental Anxiety | 1 | 2002 | 2 | 0.180 |
Why?
|
| Anesthesia, Dental | 1 | 2002 | 4 | 0.180 |
Why?
|
| Risk Factors | 9 | 2013 | 5961 | 0.180 |
Why?
|
| Time Factors | 11 | 2018 | 5580 | 0.180 |
Why?
|
| Placebos | 4 | 2011 | 213 | 0.170 |
Why?
|
| Anesthesiology | 3 | 1999 | 168 | 0.170 |
Why?
|
| Thiopental | 2 | 1997 | 16 | 0.160 |
Why?
|
| Infusions, Intravenous | 3 | 2014 | 423 | 0.160 |
Why?
|
| Anesthetics, Combined | 1 | 1999 | 4 | 0.150 |
Why?
|
| Prospective Studies | 9 | 2013 | 4671 | 0.150 |
Why?
|
| Azepines | 1 | 2019 | 28 | 0.150 |
Why?
|
| Alfentanil | 1 | 1999 | 2 | 0.150 |
Why?
|
| Drug Tolerance | 3 | 1996 | 64 | 0.150 |
Why?
|
| Research Design | 2 | 2013 | 631 | 0.150 |
Why?
|
| Pentazocine | 1 | 1998 | 2 | 0.150 |
Why?
|
| Citrates | 1 | 2018 | 29 | 0.150 |
Why?
|
| Attention | 5 | 2007 | 413 | 0.140 |
Why?
|
| Anesthesia | 2 | 1999 | 175 | 0.140 |
Why?
|
| Hypnotics and Sedatives | 2 | 1996 | 142 | 0.140 |
Why?
|
| Psychotropic Drugs | 1 | 1999 | 82 | 0.140 |
Why?
|
| Ethers | 1 | 1997 | 14 | 0.140 |
Why?
|
| Verapamil | 2 | 1997 | 34 | 0.140 |
Why?
|
| Randomized Controlled Trials as Topic | 4 | 2013 | 935 | 0.140 |
Why?
|
| Adjuvants, Anesthesia | 1 | 1997 | 4 | 0.140 |
Why?
|
| Piperidines | 1 | 1999 | 171 | 0.140 |
Why?
|
| Neuropsychological Tests | 4 | 2012 | 549 | 0.130 |
Why?
|
| Risk | 2 | 2013 | 668 | 0.130 |
Why?
|
| Individuality | 3 | 2008 | 114 | 0.130 |
Why?
|
| Nalbuphine | 1 | 1997 | 3 | 0.130 |
Why?
|
| Calcium Channel Blockers | 1 | 1997 | 122 | 0.130 |
Why?
|
| Accidents, Occupational | 1 | 1996 | 8 | 0.130 |
Why?
|
| Buprenorphine | 1 | 1997 | 51 | 0.130 |
Why?
|
| Sulfonamides | 1 | 2019 | 337 | 0.130 |
Why?
|
| Anti-Anxiety Agents | 1 | 1996 | 23 | 0.130 |
Why?
|
| Pyrimidines | 1 | 2019 | 386 | 0.120 |
Why?
|
| Methadone | 1 | 1996 | 50 | 0.120 |
Why?
|
| Dronabinol | 3 | 1992 | 59 | 0.120 |
Why?
|
| Self Administration | 3 | 2008 | 76 | 0.120 |
Why?
|
| Central Nervous System Stimulants | 1 | 2018 | 235 | 0.120 |
Why?
|
| Flumazenil | 1 | 1995 | 8 | 0.120 |
Why?
|
| Accidents, Traffic | 1 | 1996 | 104 | 0.120 |
Why?
|
| Basal Cell Nevus Syndrome | 1 | 2015 | 4 | 0.110 |
Why?
|
| Practice Guidelines as Topic | 2 | 2012 | 1096 | 0.110 |
Why?
|
| Substance Withdrawal Syndrome | 1 | 1995 | 53 | 0.110 |
Why?
|
| Miosis | 3 | 2004 | 10 | 0.110 |
Why?
|
| Anilides | 1 | 2015 | 46 | 0.110 |
Why?
|
| Breath Tests | 4 | 2001 | 58 | 0.110 |
Why?
|
| Treatment Outcome | 4 | 2019 | 9175 | 0.110 |
Why?
|
| Respiratory Mechanics | 2 | 2008 | 114 | 0.110 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 1996 | 249 | 0.110 |
Why?
|
| Quaternary Ammonium Compounds | 1 | 2014 | 82 | 0.110 |
Why?
|
| Nifedipine | 1 | 1993 | 26 | 0.100 |
Why?
|
| Population | 1 | 2013 | 37 | 0.100 |
Why?
|
| Radioimmunoassay | 1 | 1993 | 150 | 0.100 |
Why?
|
| Stress, Physiological | 1 | 1995 | 252 | 0.100 |
Why?
|
| Endpoint Determination | 1 | 2013 | 59 | 0.100 |
Why?
|
| Anesthesia, Intravenous | 1 | 1993 | 36 | 0.100 |
Why?
|
| Hair | 1 | 1993 | 56 | 0.100 |
Why?
|
| Social Environment | 2 | 1992 | 195 | 0.100 |
Why?
|
| Ondansetron | 1 | 1993 | 21 | 0.100 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2013 | 178 | 0.100 |
Why?
|
| Pyridines | 1 | 2015 | 319 | 0.100 |
Why?
|
| Tobacco Smoke Pollution | 1 | 1993 | 26 | 0.100 |
Why?
|
| Retrospective Studies | 4 | 2019 | 10287 | 0.100 |
Why?
|
| Substance Abuse, Intravenous | 1 | 1993 | 66 | 0.090 |
Why?
|
| Cycloparaffins | 1 | 1992 | 5 | 0.090 |
Why?
|
| Terminology as Topic | 1 | 2013 | 229 | 0.090 |
Why?
|
| Toxicity Tests, Acute | 1 | 2011 | 3 | 0.090 |
Why?
|
| Pregabalin | 1 | 2011 | 7 | 0.090 |
Why?
|
| Thinking | 1 | 2012 | 39 | 0.090 |
Why?
|
| Respiratory Rate | 1 | 2011 | 25 | 0.090 |
Why?
|
| Neurology | 1 | 2012 | 83 | 0.090 |
Why?
|
| Social Isolation | 1 | 1992 | 71 | 0.090 |
Why?
|
| Drug Discovery | 1 | 2012 | 118 | 0.090 |
Why?
|
| 3,4-Methylenedioxyamphetamine | 2 | 1990 | 5 | 0.090 |
Why?
|
| Socioeconomic Factors | 1 | 2013 | 640 | 0.080 |
Why?
|
| Drug Administration Schedule | 2 | 2019 | 873 | 0.080 |
Why?
|
| Leukemia, Myeloid | 1 | 2011 | 252 | 0.080 |
Why?
|
| Plants, Toxic | 2 | 1987 | 25 | 0.080 |
Why?
|
| Amphetamines | 1 | 1990 | 19 | 0.080 |
Why?
|
| Psychopharmacology | 1 | 2009 | 26 | 0.080 |
Why?
|
| Procaine | 1 | 1989 | 11 | 0.080 |
Why?
|
| Pentobarbital | 1 | 1989 | 19 | 0.080 |
Why?
|
| Social Values | 1 | 2009 | 44 | 0.080 |
Why?
|
| Cannabis | 1 | 1990 | 40 | 0.080 |
Why?
|
| Psychological Tests | 1 | 2009 | 91 | 0.070 |
Why?
|
| Conditioning, Operant | 4 | 2008 | 68 | 0.070 |
Why?
|
| Lidocaine | 1 | 1989 | 67 | 0.070 |
Why?
|
| Cotinine | 3 | 1997 | 15 | 0.070 |
Why?
|
| Cocaine | 1 | 1989 | 81 | 0.070 |
Why?
|
| Methamphetamine | 1 | 1990 | 104 | 0.070 |
Why?
|
| Drug Evaluation | 1 | 2008 | 136 | 0.070 |
Why?
|
| Norepinephrine | 3 | 2005 | 174 | 0.070 |
Why?
|
| Placebo Effect | 1 | 2008 | 35 | 0.070 |
Why?
|
| Drug Design | 1 | 2008 | 133 | 0.070 |
Why?
|
| Health Surveys | 1 | 2008 | 245 | 0.070 |
Why?
|
| Clinical Trials as Topic | 1 | 2012 | 1179 | 0.070 |
Why?
|
| Reward | 1 | 2009 | 209 | 0.060 |
Why?
|
| Pharmaceutical Preparations | 1 | 2008 | 97 | 0.060 |
Why?
|
| Smoke | 1 | 1986 | 29 | 0.060 |
Why?
|
| Case-Control Studies | 1 | 2011 | 1957 | 0.060 |
Why?
|
| Neoplasms | 2 | 2019 | 3248 | 0.060 |
Why?
|
| Controlled Clinical Trials as Topic | 1 | 2006 | 22 | 0.060 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2008 | 209 | 0.060 |
Why?
|
| Middle Aged | 8 | 2019 | 28368 | 0.060 |
Why?
|
| Ambulatory Surgical Procedures | 3 | 1995 | 82 | 0.060 |
Why?
|
| Drug Therapy, Combination | 2 | 2019 | 813 | 0.060 |
Why?
|
| Self Concept | 1 | 2005 | 137 | 0.060 |
Why?
|
| Water | 2 | 1997 | 307 | 0.050 |
Why?
|
| Forearm | 1 | 2004 | 31 | 0.050 |
Why?
|
| Heroin Dependence | 2 | 2011 | 16 | 0.050 |
Why?
|
| Serotonin | 1 | 2005 | 219 | 0.050 |
Why?
|
| Drug Synergism | 2 | 1998 | 317 | 0.050 |
Why?
|
| Prevalence | 1 | 2008 | 1349 | 0.050 |
Why?
|
| Oxygen | 3 | 1999 | 781 | 0.050 |
Why?
|
| Lysergic Acid Diethylamide | 1 | 2004 | 27 | 0.050 |
Why?
|
| Reinforcement Schedule | 3 | 2008 | 16 | 0.050 |
Why?
|
| Plant Extracts | 1 | 2004 | 248 | 0.050 |
Why?
|
| Volunteers | 1 | 2001 | 22 | 0.040 |
Why?
|
| Adolescent | 5 | 1993 | 9895 | 0.040 |
Why?
|
| Random Allocation | 2 | 1993 | 325 | 0.040 |
Why?
|
| Amitriptyline | 1 | 2001 | 11 | 0.040 |
Why?
|
| Statistics as Topic | 1 | 2002 | 236 | 0.040 |
Why?
|
| Gait | 1 | 2001 | 85 | 0.040 |
Why?
|
| Antidepressive Agents | 1 | 2001 | 113 | 0.040 |
Why?
|
| Sleep | 2 | 1996 | 458 | 0.040 |
Why?
|
| Consumer Behavior | 1 | 1999 | 32 | 0.040 |
Why?
|
| Sensation | 1 | 1999 | 52 | 0.040 |
Why?
|
| Response Evaluation Criteria in Solid Tumors | 1 | 2019 | 60 | 0.040 |
Why?
|
| Indazoles | 1 | 2019 | 61 | 0.040 |
Why?
|
| Risk Assessment | 2 | 2019 | 2480 | 0.040 |
Why?
|
| Incidence | 1 | 2003 | 1715 | 0.040 |
Why?
|
| Drug Utilization | 1 | 1999 | 69 | 0.040 |
Why?
|
| Maximum Tolerated Dose | 1 | 2019 | 271 | 0.040 |
Why?
|
| Attitude | 1 | 1999 | 137 | 0.040 |
Why?
|
| Patient Satisfaction | 1 | 2001 | 514 | 0.030 |
Why?
|
| Aged | 4 | 2019 | 20968 | 0.030 |
Why?
|
| Diltiazem | 1 | 1997 | 7 | 0.030 |
Why?
|
| Nimodipine | 1 | 1997 | 12 | 0.030 |
Why?
|
| Mental Competency | 1 | 1997 | 50 | 0.030 |
Why?
|
| Cross-Sectional Studies | 1 | 2003 | 1876 | 0.030 |
Why?
|
| Neoplasm Invasiveness | 1 | 2019 | 580 | 0.030 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2019 | 883 | 0.030 |
Why?
|
| Infusion Pumps | 1 | 1996 | 27 | 0.030 |
Why?
|
| Patient Safety | 1 | 2019 | 223 | 0.030 |
Why?
|
| Motor Activity | 1 | 1999 | 332 | 0.030 |
Why?
|
| Disease-Free Survival | 1 | 2019 | 1196 | 0.030 |
Why?
|
| Behavior, Animal | 1 | 1999 | 394 | 0.030 |
Why?
|
| Recurrence | 1 | 1999 | 1218 | 0.030 |
Why?
|
| Columbidae | 4 | 1990 | 4 | 0.030 |
Why?
|
| Work Schedule Tolerance | 1 | 1996 | 37 | 0.030 |
Why?
|
| Long-Term Care | 1 | 1996 | 63 | 0.030 |
Why?
|
| Administration, Intranasal | 1 | 1996 | 140 | 0.030 |
Why?
|
| Coffee | 1 | 1995 | 10 | 0.030 |
Why?
|
| Single-Blind Method | 1 | 1996 | 162 | 0.030 |
Why?
|
| Survival Analysis | 1 | 2019 | 1546 | 0.030 |
Why?
|
| United States | 2 | 2012 | 7768 | 0.030 |
Why?
|
| Sleep Deprivation | 1 | 1996 | 133 | 0.030 |
Why?
|
| Informed Consent | 1 | 1997 | 281 | 0.030 |
Why?
|
| Pressure | 1 | 1995 | 175 | 0.030 |
Why?
|
| Chronic Disease | 1 | 1998 | 983 | 0.030 |
Why?
|
| Follow-Up Studies | 1 | 2002 | 3927 | 0.030 |
Why?
|
| Personality Inventory | 1 | 1994 | 112 | 0.030 |
Why?
|
| Age Factors | 1 | 2019 | 1963 | 0.030 |
Why?
|
| Temperature | 1 | 1995 | 426 | 0.030 |
Why?
|
| Nervous System Diseases | 1 | 1995 | 172 | 0.030 |
Why?
|
| Reflex, Pupillary | 1 | 1994 | 7 | 0.030 |
Why?
|
| Sufentanil | 1 | 1993 | 3 | 0.030 |
Why?
|
| Neoplasm Staging | 1 | 2019 | 2086 | 0.030 |
Why?
|
| Smell | 1 | 1994 | 121 | 0.020 |
Why?
|
| Generalization, Stimulus | 2 | 1990 | 3 | 0.020 |
Why?
|
| Models, Biological | 1 | 1999 | 1809 | 0.020 |
Why?
|
| Pulse | 1 | 1992 | 16 | 0.020 |
Why?
|
| Internationality | 1 | 2012 | 76 | 0.020 |
Why?
|
| Tetrahydronaphthalenes | 1 | 1992 | 16 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2019 | 3110 | 0.020 |
Why?
|
| N-Methyl-3,4-methylenedioxyamphetamine | 2 | 1990 | 74 | 0.020 |
Why?
|
| Hunger | 1 | 1992 | 22 | 0.020 |
Why?
|
| Verbal Behavior | 1 | 1992 | 33 | 0.020 |
Why?
|
| Animals | 6 | 1999 | 28891 | 0.020 |
Why?
|
| Personality Assessment | 1 | 1992 | 99 | 0.020 |
Why?
|
| Memory, Short-Term | 3 | 2005 | 244 | 0.020 |
Why?
|
| Energy Intake | 1 | 1992 | 100 | 0.020 |
Why?
|
| Daunorubicin | 1 | 2011 | 78 | 0.020 |
Why?
|
| Bridged Bicyclo Compounds, Heterocyclic | 1 | 1992 | 103 | 0.020 |
Why?
|
| Ketone Bodies | 1 | 1991 | 16 | 0.020 |
Why?
|
| Dopamine | 2 | 1983 | 283 | 0.020 |
Why?
|
| Hormones | 1 | 2011 | 144 | 0.020 |
Why?
|
| Cytarabine | 1 | 2011 | 225 | 0.020 |
Why?
|
| Carbon Dioxide | 1 | 1992 | 212 | 0.020 |
Why?
|
| Fenfluramine | 1 | 1990 | 20 | 0.020 |
Why?
|
| Drinking Behavior | 1 | 1990 | 13 | 0.020 |
Why?
|
| Glycosuria | 1 | 1989 | 4 | 0.020 |
Why?
|
| Sodium Chloride | 1 | 1990 | 88 | 0.020 |
Why?
|
| Rats, Inbred Strains | 1 | 1990 | 311 | 0.020 |
Why?
|
| Smoking Cessation | 1 | 1993 | 272 | 0.020 |
Why?
|
| Amphetamine | 1 | 1990 | 102 | 0.020 |
Why?
|
| Cocaine-Related Disorders | 1 | 2008 | 41 | 0.020 |
Why?
|
| Filtration | 1 | 1986 | 27 | 0.020 |
Why?
|
| Databases, Factual | 1 | 2010 | 1010 | 0.010 |
Why?
|
| Volatilization | 1 | 2005 | 6 | 0.010 |
Why?
|
| Blood Glucose | 1 | 1989 | 873 | 0.010 |
Why?
|
| Time Perception | 1 | 2005 | 24 | 0.010 |
Why?
|
| Verbal Learning | 1 | 2005 | 30 | 0.010 |
Why?
|
| Problem Solving | 1 | 2005 | 55 | 0.010 |
Why?
|
| Discrimination Learning | 1 | 2005 | 65 | 0.010 |
Why?
|
| Conscious Sedation | 1 | 2005 | 78 | 0.010 |
Why?
|
| Rats | 1 | 1990 | 4155 | 0.010 |
Why?
|
| Stereotyped Behavior | 1 | 1983 | 13 | 0.010 |
Why?
|
| Telencephalon | 1 | 1982 | 32 | 0.010 |
Why?
|
| Desipramine | 1 | 2001 | 9 | 0.010 |
Why?
|
| Paroxetine | 1 | 2001 | 26 | 0.010 |
Why?
|
| Brain | 1 | 2011 | 2482 | 0.010 |
Why?
|
| Antineoplastic Agents | 1 | 2011 | 2418 | 0.010 |
Why?
|
| Oxygen Consumption | 1 | 2001 | 253 | 0.010 |
Why?
|
| Lung | 1 | 1987 | 1384 | 0.010 |
Why?
|
| Stress, Psychological | 1 | 1983 | 347 | 0.010 |
Why?
|
| Droperidol | 1 | 1995 | 3 | 0.010 |
Why?
|
| Ketamine | 1 | 1995 | 27 | 0.010 |
Why?
|
| Reference Standards | 1 | 1995 | 150 | 0.010 |
Why?
|
| Postoperative Period | 1 | 1991 | 318 | 0.010 |
Why?
|
| Learning | 1 | 1993 | 305 | 0.000 |
Why?
|
| Apomorphine | 1 | 1983 | 10 | 0.000 |
Why?
|
| Haloperidol | 1 | 1983 | 29 | 0.000 |
Why?
|
| Pons | 1 | 1982 | 26 | 0.000 |
Why?
|
| Substantia Nigra | 1 | 1982 | 30 | 0.000 |
Why?
|
| Brain Chemistry | 1 | 1983 | 120 | 0.000 |
Why?
|
| Basal Ganglia | 1 | 1982 | 47 | 0.000 |
Why?
|
| Olfactory Bulb | 1 | 1982 | 42 | 0.000 |
Why?
|
| Corpus Striatum | 1 | 1982 | 92 | 0.000 |
Why?
|
| Eating | 1 | 1983 | 165 | 0.000 |
Why?
|
| Neural Pathways | 1 | 1982 | 333 | 0.000 |
Why?
|